Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026

BOSTON, October 1, 2026 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced that the company will present new interim data from its Phase 1 clinical trial of ER-100 in patients with glaucoma in an oral session at Eyecelerator @ American Academy of Ophthalmology (AAO) […] The post Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026 appeared first on Life Biosciences, Inc. .